Health and Fitness FDA Approves New Drug to Treat Schizophrenia and Bipolar Disorder by Press Release on September 17, 2015 Press Release Author More in Health and Fitness: On Hantavirus, Park Forest Officials Urge Caution May 18, 2026 Rep. Kelly Condemns FDA Approval of Flavored E-Cigarettes May 6, 2026 Park Forest Aligns With Illinois Guidance on Childhood Vaccines Amid Federal Changes January 11, 2026 Silver Spring, Maryland–(ENEWSPF)–September 17, 2015. The U.S. Food and Drug Administration today approved Vraylar (cariprazine) capsules to treat schizophrenia and bipolar disorder in adults.